



(51) International Patent Classification:

A61K 31/517 (2006.01) **C07D 407/12** (2006.01)
A61K 31/519 (2006.01) **C07D 413/14** (2006.01)
A61K 31/5377 (2006.01) **C07D 417/12** (2006.01)
C07D 239/70 (2006.01) **C07D 471/04** (2006.01)
C07D 401/12 (2006.01) **C07D 491/052** (2006.01)
C07D 401/14 (2006.01) **C07D 491/08** (2006.01)
C07D 403/12 (2006.01) **C07D 491/113** (2006.01)
C07D 403/14 (2006.01)

(21) International Application Number:

PCT/US2010/043487

(22) International Filing Date:

28 July 2010 (28.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/230,202 31 July 2009 (31.07.2009) US
 61/324,201 14 April 2010 (14.04.2010) US

(71) **Applicant** (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **BOY, Kenneth M.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **GUERINON, Jason M.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **MACOR, John E.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **OLSON, Richard E.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SHI, Jianliang** [US/US]; Bris-

tol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **THOMPSON, III, Lorin A.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **WU, Yong-Jin** [CA/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **XU, Li** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **ZHANG, Yunhui** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **ZUEV, Dmitry S.** [US/US]; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).


(74) **Agents:** **LEVIS, John F.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) **Title:** COMPOUNDS FOR THE REDUCTION OF β -AMYLOID PRODUCTION



(57) **Abstract:** The present disclosure provides a series of compounds of the formula (I) which modulate β -amyloid peptide (β -AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β -amyloid peptide (β -AP) production.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). **Published:**

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*